Ernexa Therapeutics Inc. — Director's Dealing 2021

Apr 19, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-03-25

Reporting Person: DENNY GEORGE P III (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4850117	Indirect
Common Stock	34585	Indirect
Common Stock	4094	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (19196)		Indirect

Footnotes

F1: The reporting person disclaims beneficial ownership of the shares held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein.

F2: The reporting person holds 71,306 shares of Series A preferred stock, which are currently convertible into 19,196 shares of common stock. The reporting person has the right at any time to convert the shares of Series A preferred stock into that number of fully paid and nonassessable shares of common stock that equals the number of shares of Series A preferred stock that are surrendered for conversion divided by the conversion rate. The conversion rate was initially 100% and is subject to adjustment as provided in the Issuer's restated certificate of incorporation, as amended. The Series A preferred stock has no expiration date.